Combination therapy versus monotherapy in the treatment of recalcitrant warts: A clinical and immunological study.
Treatment of recalcitrant warts represents a continuing therapeutic challenge. Combination therapies can help improve treatment response, decrease adverse effects, and reduce recurrence. To compare the efficacy, safety and immunological effects of a combined acitretin-intralesional Candida antigen against acitretin alone and Candida antigen alone for intractable warts. Sixty adult patients with intractable warts were included in this study. Patients were subdivided into three groups, each containing 20 patients. Acitretin alone was taken by patients of group I, Candida antigen alone was injected in patients of group II, and group III received a combination of intralesional Candida antigen and acitretin. Serum cytokine levels of IL-10 and IFN-γ were measured before and after therapy in the studied groups. Total resolution of warts was achieved in 8 patients (40%) of the acitretin alone group, 9 patients (45%) of the Candida antigen alone group and 15 patients (75%) of the combination therapy group. The therapeutic response was statistically higher in the combined acitretin-Candida antigen group as compared with either agent alone. Adverse effects were non-significant in the three groups. There were no statistically significant differences in the serum levels of IFN-γ and IL-10 between responders and non-responders after therapy in the three studied groups. The combination therapy of acitretin + Candida antigen is superior to either agent alone. Serum cytokine levels of IL-10 and IFN-γ were not associated with clearance or persistence of warts in any of the studied groups.